Description: AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development.
Home Page: www.abcellera.com
ABCL Technical Analysis
2215 Yukon Street
Vancouver,
BC
V5Y 0A1
Canada
Phone:
604 559 9905
Officers
| Name | Title |
|---|---|
| Dr. Carl L.G. Hansen Ph.D. | CEO, Pres & Chairperson |
| Mr. Andrew Booth M.B.A. | Chief Financial Officer |
| Dr. Veronique Lecault Ph.D. | COO & Director |
| Mr. Tryn T. Stimart Esq., J.D. | Chief Legal Officer, Chief Compliance Officer & Corp. Sec. |
| Dr. Ester Falconer Ph.D. | Chief Technology Officer |
| Mr. Bo Barnhart Ph.D. | Scientific Director |
| Ms. Tiffany Chiu B.Sc., Ph.D. | VP of Communications |
| Mr. Murray McCutcheon Ph.D. | VP of Corp. Devel. |
| Alexandra Weirich M.Sc. | Mang. of Marketing & Communications |
| Caitlin Webster CIPD, M.Sc. | Sr. Mang. of People & Culture |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 27.4725 |
|---|---|
| Trailing PE: | 12.2436 |
| Price-to-Book MRQ: | 2.3182 |
| Price-to-Sales TTM: | 4.9327 |
| IPO Date: | 2020-12-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 475 |